MARKET

ADIL

ADIL

Adial Pharmaceuticals Inc
NASDAQ
2.560
-0.020
-0.78%
After Hours: 2.561 +0.001 +0.02% 18:08 06/26 EDT
OPEN
2.520
PREV CLOSE
2.580
HIGH
2.655
LOW
2.500
VOLUME
28.99K
TURNOVER
--
52 WEEK HIGH
18.90
52 WEEK LOW
1.310
MARKET CAP
5.49M
P/E (TTM)
-0.2577
1D
5D
1M
3M
1Y
5Y
1D
Adial Pharmaceuticals Form 13G Shows Coastlands Capital Partners Discloses 9.98% Passive Stake In Co. As Of June 17
Benzinga · 3d ago
COASTLANDS CAPITAL LP REPORTS 9.98% PASSIVE STAKE IN ADIAL PHARMACEUTICALS AS OF JUNE 17 - SEC FILING
Reuters · 3d ago
Weekly Report: what happened at ADIL last week (0615-0619)?
Weekly Report · 6d ago
Adial Pharmaceuticals grants inducement equity awards to new chief development officer, strategy EVP
PUBT · 06/16 12:04
Adial Pharmaceuticals appoints Matthew Davidson chief development officer, Julie Saiki EVP strategy
PUBT · 06/16 12:03
ADIAL PHARMACEUTICALS EXPANDS EXECUTIVE LEADERSHIP TEAM AND CLOSES PIPE FINANCING
Reuters · 06/16 12:00
Press Release: Adial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financing
Dow Jones · 06/16 12:00
Adial Pharmaceuticals director Wendy B. Young files initial beneficial ownership statement
PUBT · 06/16 10:11
More
About ADIL
Adial Pharmaceuticals, Inc. is a biopharmaceutical company. Its lead program is AT177, a proprietary colon‑targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure in development for ulcerative colitis. AT177 is a fully synthetic, patented, oral AhR agonist designed to restore mucosal immune homeostasis at the site of disease with minimal systemic exposure. AT177's active ingredient is a prodrug of indirubin, a potent AhR agonist within indigo naturalis, a botanical extract with clinical efficacy in ulcerative colitis. AT177's colon-targeted formulation delivers therapeutic AhR engagement directly to the colonic mucosa with exquisite gut restriction, minimizing the systemic AhR exposure associated with adverse effects. Its historical investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder in heavy drinking patients.

Webull offers Adial Pharmaceuticals Inc stock information, including NASDAQ: ADIL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADIL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ADIL stock methods without spending real money on the virtual paper trading platform.